Armored Inducible Expression of IL-12 Enhances Antitumor Activity of Glypican-3–Targeted Chimeric Antigen Receptor–Engineered T Cells in Hepatocellular Carcinoma

El-Serag, 2007, Hepatocellular carcinoma: epidemiology and molecular carcinogenesis., Gastroenterology, 132, 2557, 10.1053/j.gastro.2007.04.061

Altekruse, 2009, Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005., J. Clin. Oncol., 27, 1485, 10.1200/JCO.2008.20.7753

Clavien, 2007, Strategies for safer liver surgery and partial liver transplantation., N. Engl. J. Med., 356, 1545, 10.1056/NEJMra065156

Raza, 2014, Hepatocellular carcinoma review: current treatment, and evidence-based medicine., World J. Gastroenterol., 20, 4115, 10.3748/wjg.v20.i15.4115

Couzin-Frankel, 2013, Breakthrough of the year 2013. Cancer immunotherapy., Science, 342, 1432, 10.1126/science.342.6165.1432

Grupp, 2013, Chimeric antigen receptor-modified T cells for acute lymphoid leukemia., N. Engl. J. Med., 368, 1509, 10.1056/NEJMoa1215134

Davila, 2014, Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia., Sci. Transl. Med., 6, 10.1126/scitranslmed.3008226

Gill, 2015, Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies., Immunol. Rev., 263, 68, 10.1111/imr.12243

Maude, 2014, Chimeric antigen receptor T cells for sustained remissions in leukemia., N. Engl. J. Med., 371, 1507, 10.1056/NEJMoa1407222

Lamers, 2013, Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity., Mol. Ther., 904

Beatty, 2016, Chimeric antigen receptor-modified T cells for the treatment of solid tumors: defining the challenges and next steps., Pharmacol. Ther., 166, 30, 10.1016/j.pharmthera.2016.06.010

Feng, 2017, Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers., Protein Cell, 838

Ahmed, 2015, Human epidermal growth factor receptor 2 (HER2) -specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma., J. Clin. Oncol., 33, 1688, 10.1200/JCO.2014.58.0225

Beatty, 2014, Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies., Cancer Immunol. Res., 2, 112, 10.1158/2326-6066.CIR-13-0170

Scarfò, 2017, Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment., J. Immunother. Cancer, 5, 28, 10.1186/s40425-017-0230-9

Sadelain, 2013, The basic principles of chimeric antigen receptor design., Cancer Discov., 3, 388, 10.1158/2159-8290.CD-12-0548

Yeku, 2016, Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy., Biochem. Soc. Trans., 44, 412, 10.1042/BST20150291

Trinchieri, 2003, Interleukin-12 and the regulation of innate resistance and adaptive immunity., Nat. Rev. Immunol., 3, 133, 10.1038/nri1001

Curtsinger, 2003, Signal 3 determines tolerance versus full activation of naive CD8 T cells: dissociating proliferation and development of effector function., J. Exp. Med., 197, 1141, 10.1084/jem.20021910

Ma, 1996, The interleukin 12 p40 gene promoter is primed by interferon gamma in monocytic cells., J. Exp. Med., 183, 147, 10.1084/jem.183.1.147

Chan, 1991, Induction of interferon gamma production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers., J. Exp. Med., 173, 869, 10.1084/jem.173.4.869

Kerkar, 2011, IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors., J. Clin. Invest., 121, 4746, 10.1172/JCI58814

Tahara, 1996, Murine models of cancer cytokine gene therapy using interleukin-12., Ann. N. Y. Acad. Sci., 795, 275, 10.1111/j.1749-6632.1996.tb52677.x

Leonard, 1997, Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production., Blood, 90, 2541

Cohen, 1995, IL-12 deaths: explanation and a puzzle., Science, 270, 908, 10.1126/science.270.5238.908.a

Koneru, 2015, IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo., OncoImmunology, 4, 10.4161/2162402X.2014.994446

Chinnasamy, 2012, Local delivery of interleukin-12 using T cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice., Clin. Cancer. Res., 1672

Haruyama, 2016, Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma., World J. Gastroenterol., 22, 275, 10.3748/wjg.v22.i1.275

Zhu, 2013, First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma., Clin. Cancer. Res., 920

Ikeda, 2014, Japanese phase I study of GC33, a humanized antibody against glypican-3 for advanced hepatocellular carcinoma., Cancer Sci., 105, 455, 10.1111/cas.12368

Sawada, 2012, Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival., Clin. Cancer. Res., 3686

Zhai, 2017, A phase I study of anti-GPC3 chimeric antigen receptor modified T cells (GPC3 CAR-T) in Chinese patients with refractory or relapsed GPC3+ hepatocellular carcinoma (r/r GPC3+ HCC)., J. Clin. Oncol., 35, 3049, 10.1200/JCO.2017.35.15_suppl.3049

Zhou, 2018, Glypican-3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment., Med. Res. Rev., 741

Bi, 2017, Treatment of hepatocellular carcinoma with a GPC3-targeted bispecific T cell engager., Oncotarget, 8, 52866, 10.18632/oncotarget.17905

Gao, 2014, Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma., Clin. Cancer. Res., 6418

Jiang, 2017, Efficient growth suppression in pancreatic cancer PDX model by fully human anti-mesothelin CAR-T cells., Protein Cell., 926

Zhang, 2011, Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment., Mol. Ther., 751

Hooijberg, 2000, NFAT-controlled expression of GFP permits visualization and isolation of antigen-stimulated primary human T cells., Blood, 96, 459, 10.1182/blood.V96.2.459

Kerkar, 2010, Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts., Cancer Res., 70, 6725, 10.1158/0008-5472.CAN-10-0735

Chinnasamy, 2010, Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice., J. Clin. Invest., 120, 3953, 10.1172/JCI43490

Longo, 2013, Transient mammalian cell transfection with polyethylenimine (PEI)., Methods Enzymol., 529, 227, 10.1016/B978-0-12-418687-3.00018-5

Kuroda, 2009, Simplified lentivirus vector production in protein-free media using polyethylenimine-mediated transfection., J. Virol. Methods, 157, 113, 10.1016/j.jviromet.2008.11.021

Li, 2016, Adoptive immunotherapy using T lymphocytes redirected to glypican-3 for the treatment of lung squamous cell carcinoma., Oncotarget, 7, 2496, 10.18632/oncotarget.6595

Pegram, 2012, Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning., Blood, 119, 4133, 10.1182/blood-2011-12-400044

Yeku, 2017, Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment., Sci. Rep., 7, 10541, 10.1038/s41598-017-10940-8

Lisiero, 2011, Enhanced sensitivity to IL-2 signaling regulates the clinical responsiveness of IL-12-primed CD8(+) T cells in a melanoma model., J. Immunol., 186, 5068, 10.4049/jimmunol.1003317

Hadrup, 2013, Effector CD4 and CD8 T cells and their role in the tumor microenvironment., Cancer Microenviron., 6, 123, 10.1007/s12307-012-0127-6

Yu, 2017, Chimeric antigen receptor T cells: a novel therapy for solid tumors., J. Hematol. Oncol., 10, 78, 10.1186/s13045-017-0444-9

Marigo, 2008, Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells., Immunol. Rev., 222, 162, 10.1111/j.1600-065X.2008.00602.x

Trinchieri, 1993, Producer cells of interleukin-12., Immunol. Today, 14, 237, 10.1016/0167-5699(93)90173-I

Tugues, 2015, New insights into IL-12-mediated tumor suppression., Cell Death Differ., 22, 237, 10.1038/cdd.2014.134

Hendrzak, 1996, Antitumor and antimetastatic activity of interleukin-12., Curr. Top. Microbiol. Immunol., 213, 65

Brunda, 1993, Antitumor and antimetastatic activity of interleukin 12 against murine tumors., J. Exp. Med., 178, 1223, 10.1084/jem.178.4.1223

Halin, 2002, Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature., Nat. Biotechnol., 20, 264, 10.1038/nbt0302-264

Peng, 1999, A single-chain IL-12 IgG3 antibody fusion protein retains antibody specificity and IL-12 bioactivity and demonstrates antitumor activity., J. Immunol., 163, 250, 10.4049/jimmunol.163.1.250

Dickerson, 2004, Enhancement of the antiangiogenic activity of interleukin-12 by peptide targeted delivery of the cytokine to alphavbeta3 integrin., Mol. Cancer Res., 2, 663, 10.1158/1541-7786.663.2.12

Heinzerling, 2005, Intratumoral injection of DNA encoding human interleukin 12 into patients with metastatic melanoma: clinical efficacy., Hum. Gene Ther., 16, 35, 10.1089/hum.2005.16.35

Mahvi, 2007, Intratumoral injection of IL-12 plasmid DNA--results of a phase I/IB clinical trial., Cancer Gene Ther., 14, 717, 10.1038/sj.cgt.7701064

Daud, 2008, Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma., J. Clin. Oncol., 26, 5896, 10.1200/JCO.2007.15.6794

Wagner, 2004, A strategy for treatment of Epstein-Barr virus-positive Hodgkin’s disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells., Cancer Gene Ther., 11, 81, 10.1038/sj.cgt.7700664

Zhang, 2015, Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma., Clin. Cancer. Res., 2278

Chmielewski, 2017, CAR T cells releasing IL-18 convert to T-Bethigh FoxO1low effectors that exhibit augmented activity against advanced solid tumors., Cell Reports, 21, 3205, 10.1016/j.celrep.2017.11.063

Shi, 2017, Intratumoral IL-12 gene electrotransfer-mediated regression of established B16F10 melanoma protects against rechallenge., J. Immunol., 198(1 Supplement)